Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 15 to 65 years old
- People who have been newly diagnosed with a specific type of blood cancer called Ph-negative B-cell precursor acute lymphoblastic leukemia (ALL), where at least 20% of the cancer cells carry a marker called CD19 (confirm with trial site)
- People who have not yet received any treatment for this diagnosis, apart from possibly a short course (5 days or fewer) of certain basic medications (hydroxyurea or corticosteroids)
- People whose general health and ability to carry out daily activities falls within a certain acceptable range, as measured by a standard medical scale (ECOG score of 0–3)
- People whose liver is working well enough, based on blood test results falling within accepted limits
- People whose kidneys are working well enough, based on a measure of how efficiently the kidneys filter the blood
- People who are able to understand the study and are willing to take part, and who can sign a written consent form
Who may not be able to join:
- People whose leukemia carries a specific genetic abnormality known as the Philadelphia chromosome (Ph+ or BCR-ABL1+)
- People diagnosed with T-cell acute lymphoblastic leukemia
- People diagnosed with mature B-cell leukemia or lymphoma, B-cell lymphoblastic lymphoma, or whose cancer has spread outside the bone marrow
- People diagnosed with a mixed type of acute leukemia involving more than one cell type (called MPAL)
- People whose leukemia has spread to the central nervous system (the brain and spinal cord)
- People living with HIV
- People with active hepatitis B virus (HBV) or hepatitis C virus (HCV) detected in their blood
- People with certain heart conditions, or other health conditions that the trial doctor considers unsuitable for participation
- People who are pregnant or breastfeeding
- People who do not wish to take part in the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Suning Chen, The First Affiliated Hospital of Soochow University
Phone: 86+0512-67781137
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
2-year relapse-free survival (RFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.